Article Versions Notes

Shao B, Liu X, Li H, Song G, Di L, Jiang H, Yan Y, Zhang R, Ran R, Zhang J, et al. Prognostic Value of Pretreatment Neutrophil-to-Lymphocyte Ratio in HER2-Positive Metastatic Breast Cancer. Current Oncology. 2022; 29(9):6154-6166. https://doi.org/10.3390/curroncol29090483

Shao, Bin, Xiaoran Liu, Huiping Li, Guohong Song, Lijun Di, Hanfang Jiang, Ying Yan, Ruyan Zhang, Ran Ran, Jiayang Zhang, and et al. 2022. "Prognostic Value of Pretreatment Neutrophil-to-Lymphocyte Ratio in HER2-Positive Metastatic Breast Cancer" Current Oncology 29, no. 9: 6154-6166. https://doi.org/10.3390/curroncol29090483

Shao, B., Liu, X., Li, H., Song, G., Di, L., Jiang, H., Yan, Y., Zhang, R., Ran, R., Zhang, J., Liu, Y., Wang, H., & Wang, J. (2022). Prognostic Value of Pretreatment Neutrophil-to-Lymphocyte Ratio in HER2-Positive Metastatic Breast Cancer. Current Oncology, 29(9), 6154-6166. https://doi.org/10.3390/curroncol29090483